<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>POLYMED</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">POLYMED</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="poly-medicure-limited" class="section level1">
<h1>Poly Medicure Limited</h1>
<p><a href="/reports01/index/industry/rp-MedicalEquipmentSupplies.html">Medical Equipment &amp; Supplies</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.POLYMED.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.POLYMED.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.POLYMED.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.POLYMED.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.POLYMED.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.POLYMED.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.POLYMED.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.POLYMED.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.POLYMED.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-08 </em></p>
<p>Based on the provided documents‚Äîearnings call transcript, acquisition press releases, and investor meet intimation‚Äîfor <strong>Poly Medicure Limited (POLYMED)</strong>, here is a comprehensive <strong>summary analysis</strong> covering <strong>headwinds, tailwinds, growth prospects, and key risks</strong> as of <strong>November 2025</strong>. The analysis reflects the company‚Äôs strategic direction, operational performance, and macro/micro-level dynamics affecting its business.</p>
<hr />
<div id="company-overview-background" class="section level6">
<h6>üîç <strong>Company Overview (Background)</strong></h6>
<ul>
<li><strong>Core Business</strong>: Leading Indian medical device manufacturer and exporter, with products in over 125 countries.</li>
<li><strong>Product Portfolio</strong>: Infusion, Vascular Access, Renal, Critical Care, Cardiology, Orthopedics (new entry via acquisition), etc.</li>
<li><strong>Recent Strategic Moves</strong>:
<ul>
<li>Acquisition of <strong>Citieffe Group (Italy, USA, Mexico)</strong> ‚Äì Orthopedic Trauma &amp; Extremities.</li>
<li>Acquisition of <strong>PendraCare Group (Netherlands)</strong> ‚Äì Interventional Cardiology Catheters.</li>
</ul></li>
<li><strong>Manufacturing Footprint</strong>: 12 facilities across 4 countries; expanding capacity in <strong>Faridabad (Mitral), Haridwar</strong>, and shifting from Jaipur to <strong>YEIDA (near Jewar Airport)</strong>.</li>
</ul>
<hr />
</div>
<div id="tailwinds-positive-drivers" class="section level3">
<h3>üí° <strong>Tailwinds (Positive Drivers)</strong></h3>
<div id="strong-domestic-growth-momentum" class="section level9">
<p class="heading">1. <strong>Strong Domestic Growth Momentum</strong></p>
<ul>
<li><strong>Domestic revenue growth</strong>: <strong>~17‚Äì18% YoY</strong> in Q2 and H1 FY26.</li>
<li>The <strong>private hospital segment grew 22.3%</strong>, showing strong traction against tender-driven government contracts.</li>
<li>Plans to hire <strong>over 100 sales associates in FY26</strong>, indicating high confidence in market expansion.</li>
<li>Expansion of <strong>SARATHI AI-powered training platform</strong> enhances frontline sales efficiency.</li>
<li>Launch of <strong>PACE (Polymed Academy of Clinical Excellence)</strong> strengthens KOL engagement and scientific credibility.</li>
</ul>
<blockquote>
<p>‚úÖ <em>Domestic health infrastructure is growing, supported by government policies, increasing private insurance, and unmet clinical demand‚ÄîPOLYMED is well-positioned to benefit.</em></p>
</blockquote>
<hr />
</div>
<div id="strategic-acquisitions-broaden-market-reach-tam" class="section level9">
<p class="heading">2. <strong>Strategic Acquisitions Broaden Market Reach &amp; TAM</strong></p>
<ul>
<li><strong>Citieffe Group (Orthopedics)</strong>:
<ul>
<li>Enters a <strong>$70 billion global orthopedics market</strong>, specifically in high-growth trauma &amp; extremities segment.</li>
<li>EV of <strong>INR 324 crores (EUR 31M)</strong>, with <strong>15% sales growth and 14% EBITDA growth in CY24</strong>.</li>
<li>Direct presence in <strong>US, Italy, Mexico</strong>; strong MDR &amp; FDA compliance.</li>
</ul></li>
<li><strong>PendraCare Group (Cardiology Catheters)</strong>:
<ul>
<li>Strengthens interventional cardiology portfolio; strengthens <strong>EU manufacturing &amp; distribution</strong>.</li>
<li>Expected to add <strong>~INR 280 crores of annualized revenue</strong> post-integration.</li>
</ul></li>
</ul>
<blockquote>
<p>‚úÖ These acquisitions offer <strong>global reach, technology infusion, sourcing synergies, and margin improvement potential</strong> through Indian manufacturing.</p>
</blockquote>
<hr />
</div>
<div id="robust-rd-pipeline-regulatory-advancements" class="section level9">
<p class="heading">3. <strong>Robust R&amp;D Pipeline &amp; Regulatory Advancements</strong></p>
<ul>
<li><strong>20 new products in pipeline</strong> for CE marking in Europe (calendar year 2026).</li>
<li>Already have <strong>~75 CE-certified products</strong>, with focus on <strong>Vascular Access, Critical Care, and Infusion systems</strong>.</li>
<li><strong>RisoR stent clinical trial launched (2,000 patients)</strong> in India and Europe‚Äîthe largest such trial by an Indian medtech firm.</li>
<li><strong>FDA clearance received</strong> for new IV catheter design in US; commercialization expected in Q4 FY26.</li>
</ul>
<blockquote>
<p>‚úÖ Builds long-term competitiveness and global trust in Polymed‚Äôs product quality.</p>
</blockquote>
<hr />
</div>
<div id="healthy-margins-and-growing-profitability" class="section level9">
<p class="heading">4. <strong>Healthy Margins and Growing Profitability</strong></p>
<ul>
<li><strong>Gross margin improved by +137 bps (H1 FY26 vs H1 FY25)</strong> to <strong>69%</strong>.</li>
<li><strong>Operating EBITDA margin at 26.7% (H1 FY26)</strong>, within guided range of <strong>25%-27%</strong>.</li>
<li>Higher-margin domestic mix is <strong>increasing (32% of total revenue)</strong>.</li>
<li>Despite acquisitions being margin-dilutive initially (~10% lower margins), the <strong>core business remains highly profitable</strong>.</li>
</ul>
<blockquote>
<p>‚úÖ Strong operating leverage, cost control, and premium product mix support sustained profitability.</p>
</blockquote>
<hr />
</div>
<div id="capex-expansion-and-future-capacity-building" class="section level9">
<p class="heading">5. <strong>CAPEX Expansion and Future Capacity Building</strong></p>
<ul>
<li><strong>CAPEX guidance</strong>: ~‚Çπ250 crores in FY26; similar spending expected in FY27.</li>
<li><strong>New plants under construction</strong> in <strong>Faridabad (Mitral) and Haridwar</strong>, with Phase I already operational.</li>
<li><strong>Future revenue ramp-up expected from FY27 onwards</strong>, enhancing scalability.</li>
<li>Acquisition of adjacent land via NCLT (Himalayan Mineral Waters) increases site size in Haridwar for future expansion.</li>
</ul>
<blockquote>
<p>‚úÖ Investments position POLYMED for robust supply chain resilience and export-ready scale.</p>
</blockquote>
<hr />
</div>
</div>
<div id="headwinds-challenges-pressures" class="section level3">
<h3>‚ö†Ô∏è <strong>Headwinds (Challenges &amp; Pressures)</strong></h3>
<div id="international-markets-facing-volatility" class="section level9">
<p class="heading">1. <strong>International Markets Facing Volatility</strong></p>
<ul>
<li><strong>Europe faced double-digit degrowth (-9.6% YoY)</strong> due to:
<ul>
<li><strong>Chinese dumping</strong> of cheaper medical devices (due to tariffs in US).</li>
<li>Inventory overhang from 2024.</li>
<li>Geopolitical and regulatory changes (e.g., EU MDR re-certification).</li>
</ul></li>
<li>Sequential improvement in Q2 (+5% quarter-on-quarter) shows early <strong>green shoots</strong>, but full recovery not yet visible.</li>
</ul>
<blockquote>
<p>üîÑ Recovery expected in H2 and into FY27 with new product launches and regulatory clearance.</p>
</blockquote>
<hr />
</div>
<div id="us-market-downturn-due-to-tariffs-regulatory-hurdles" class="section level9">
<p class="heading">2. <strong>US Market Downturn Due to Tariffs &amp; Regulatory Hurdles</strong></p>
<ul>
<li><strong>50% tariff</strong> on Indian medical devices makes exports <strong>economically unviable</strong>.</li>
<li><strong>FDA no longer accepts Indian lab data</strong> ‚Äì forcing companies to re-test all products in US labs (delayed timelines, higher costs).</li>
<li>Only <strong>one product launched</strong> with a major US client so far; other products delayed.</li>
<li>Initial commercial supplies expected only in <strong>early Q4 FY26</strong>, and new approvals only by <strong>mid-FY27</strong>.</li>
</ul>
<blockquote>
<p>‚è≥ US growth delayed significantly; currently a ‚Äúwait-and-watch‚Äù market.</p>
</blockquote>
<hr />
</div>
<div id="renal-segment-growth-impacted-by-gst-transition" class="section level9">
<p class="heading">3. <strong>Renal Segment Growth Impacted by GST Transition</strong></p>
<ul>
<li>Q2 growth slowed to <strong>+18% YoY (from earlier high-growth rates)</strong> due to inventory realignment.</li>
<li>Full-year revenue guidance revised down from <strong>Rs. 220‚Äì250 crores to ~Rs. 200 crores</strong>.</li>
<li>However, <strong>&gt;200 dialysis machines sold in H1</strong> supports long-term service tie-in and consumable demand.</li>
</ul>
<blockquote>
<p>‚öñÔ∏è Short-term headwind, but fundamental demand remains strong.</p>
</blockquote>
<hr />
</div>
<div id="government-business-shrinking-deliberately" class="section level9">
<p class="heading">4. <strong>Government Business Shrinking Deliberately</strong></p>
<ul>
<li>Govt. segment <strong>down 14% YoY</strong>; now only ~10% of domestic revenue.</li>
<li>Intentional strategy due to <strong>low-margin, L1-driven tenders</strong>.</li>
<li>Focus shift to <strong>higher-margin private hospital sales</strong>.</li>
</ul>
<blockquote>
<p>‚úÖ Long-term positive, but causes short-term revenue trade-offs.</p>
</blockquote>
<hr />
</div>
</div>
<div id="growth-prospects-35-year-outlook" class="section level3">
<h3>üöÄ <strong>Growth Prospects (3‚Äì5 Year Outlook)</strong></h3>
<table>
<colgroup>
<col width="37%" />
<col width="62%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Segment</strong></th>
<th><strong>Growth Drivers</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Domestic Market</strong></td>
<td>Targeting <strong>28‚Äì30% YoY growth</strong> in FY26; building sales force, PACE academy, and clinical engagement.</td>
</tr>
<tr class="even">
<td><strong>Cardiology</strong></td>
<td>4,000+ stents implanted in H1; R&amp;D pipeline (DES, drug-eluting balloons); <strong>acquisition of PendraCare</strong> for front-end EU presence.</td>
</tr>
<tr class="odd">
<td><strong>Critical Care</strong></td>
<td>Already present in 500+ hospitals; <strong>&gt;90% import-dependent market</strong>; high margin opportunity; targeting Tier-1 hospitals.</td>
</tr>
<tr class="even">
<td><strong>Orthopedics (via Citieffe)</strong></td>
<td>Entry into <strong>global $70B segment</strong>; plans to expand into <strong>plates and joint replacements</strong>; synergies via Indian manufacturing.</td>
</tr>
<tr class="odd">
<td><strong>Export Markets</strong></td>
<td>Expect <strong>double-digit export growth next year</strong> as European inventory normalizes and CE-marked products launch.</td>
</tr>
<tr class="even">
<td><strong>US Market</strong></td>
<td><strong>$15‚Äì20 million product pipeline</strong> blocked by tariffs; watch for policy shifts. Recovery likely <strong>FY27</strong> onwards.</td>
</tr>
</tbody>
</table>
<blockquote>
<p>üåç <strong>Globalization Strategy</strong>: Transitioning from exporter to a global player with <strong>local R&amp;D, manufacturing, and commercial presence</strong> in key geographies.</p>
</blockquote>
<hr />
</div>
<div id="key-risks" class="section level3">
<h3>‚ö†Ô∏è <strong>Key Risks</strong></h3>
<table>
<colgroup>
<col width="18%" />
<col width="22%" />
<col width="59%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Risk</strong></th>
<th><strong>Impact</strong></th>
<th><strong>Mitigation/Commentary</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Geopolitical &amp; Trade Risks</strong></td>
<td>US 50% tariffs, China competition in Europe</td>
<td>Policy changes remain uncertain; reliance on lobbying and diversification.</td>
</tr>
<tr class="even">
<td><strong>Integration Risk (Acquisitions)</strong></td>
<td>Citieffe &amp; PendraCare integration could take 1‚Äì2 years; cultural or execution delays possible</td>
<td>Existing experience with Plan1 Health turnaround (Italy) gives confidence.</td>
</tr>
<tr class="odd">
<td><strong>Regulatory Delays</strong></td>
<td>FDA re-testing, CE certifications, hospital-level approvals delay monetization of R&amp;D</td>
<td>Proactively managing submissions; MDR certification complete for legacy products.</td>
</tr>
<tr class="even">
<td><strong>Acquisition Valuation Risk</strong></td>
<td>EV/EBITDA of 10.2x for Citieffe is premium; ROI depends on synergy realization</td>
<td>Targeting margin expansion from 15% to &gt;20% via Indian sourcing and scale.</td>
</tr>
<tr class="odd">
<td><strong>Dependence on Few Segments</strong></td>
<td>Still heavily reliant on Vascular Access (~68% of export revenue)</td>
<td>Actively diversifying into Cardiology, Critical Care, Orthopedics.</td>
</tr>
<tr class="even">
<td><strong>Execution Risk on CAPEX</strong></td>
<td>New plants delayed due to approvals, construction issues</td>
<td>Phased rollout in progress; two phases expected complete by end-2026.</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="financial-guidance-summary-fy26" class="section level3">
<h3>üìä <strong>Financial &amp; Guidance Summary (FY26)</strong></h3>
<table>
<colgroup>
<col width="16%" />
<col width="16%" />
<col width="41%" />
<col width="25%" />
</colgroup>
<thead>
<tr class="header">
<th>Metric</th>
<th>H1 FY26</th>
<th>Full Year Guidance</th>
<th>Commentary</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Revenue (Consolidated)</strong></td>
<td>‚Çπ847 crores</td>
<td>~<strong>15‚Äì16% growth</strong> (lowered from 20%)</td>
<td>Driven by domestic strength and 2 acquisitions</td>
</tr>
<tr class="even">
<td><strong>H2 Revenue Outlook</strong></td>
<td>N/A</td>
<td><strong>‚Çπ1,080‚Äì1,090 crores</strong> (~25% QoQ growth)</td>
<td>Strong rebound expected</td>
</tr>
<tr class="odd">
<td><strong>Operating EBITDA Margin</strong></td>
<td>26.7%</td>
<td>Maintain <strong>25‚Äì27%</strong></td>
<td>On track; core business healthy</td>
</tr>
<tr class="even">
<td><strong>Net Cash (post Citieffe)</strong></td>
<td>~‚Çπ800 crore (vs ‚Çπ1,109 crore earlier)</td>
<td>Net debt ~‚Çπ200 crore</td>
<td>Strong balance sheet supports future deals</td>
</tr>
<tr class="odd">
<td><strong>CAPEX</strong></td>
<td>‚Çπ150 crores (H1)</td>
<td>‚Çπ&gt;250 crores (FY26)</td>
<td>Focused on Haridwar, Faridabad expansions</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="strategic-summary-the-path-ahead" class="section level3">
<h3>üß≠ <strong>Strategic Summary: The Path Ahead</strong></h3>
<table>
<colgroup>
<col width="47%" />
<col width="52%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Aspect</strong></th>
<th><strong>Status</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Growth Model</strong></td>
<td>Dual engine: <strong>domestic expansion + global acquisitions</strong></td>
</tr>
<tr class="even">
<td><strong>Innovation</strong></td>
<td>Heavy R&amp;D in Cardiology, Critical Care; clinical trials underway</td>
</tr>
<tr class="odd">
<td><strong>Margin Story</strong></td>
<td>Premium domestic mix offsetting margin drag from acquisitions</td>
</tr>
<tr class="even">
<td><strong>Global Positioning</strong></td>
<td>Transitioning from commodity exporter to <strong>innovation-led, integrated MedTech player</strong></td>
</tr>
<tr class="odd">
<td><strong>Market Opportunity</strong></td>
<td>Huge <strong>import substitution potential</strong> in India (80‚Äì90% import-dependent in cardiology, critical care)</td>
</tr>
</tbody>
</table>
<hr />
<div id="final-verdict-bullish-medium-to-long-term-with-near-term-caution" class="section level6">
<h6>‚úÖ <strong>Final Verdict: Bullish Medium to Long Term with Near-Term Caution</strong></h6>
<div id="reasons-to-be-bullish" class="section level9">
<p class="heading"><strong>Reasons to be Bullish</strong>:</p>
<ul>
<li>Strong domestic execution &amp; growth.</li>
<li>Acquisition-led global reach and innovation.</li>
<li>High R&amp;D and regulatory readiness.</li>
<li>Healthy balance sheet and scalability.</li>
</ul>
</div>
<div id="reasons-to-be-cautious-near-term" class="section level9">
<p class="heading"><strong>Reasons to be Cautious (Near Term)</strong>:</p>
<ul>
<li>US market headwinds persist.</li>
<li>European recovery delayed.</li>
<li>Margin pressure from integration.</li>
<li>Execution risk on growth and synergy targets.</li>
</ul>
<hr />
</div>
</div>
<div id="conclusion" class="section level6">
<h6>üèÅ <strong>Conclusion</strong></h6>
<p><strong>Poly Medicure (POLYMED)</strong> is undergoing a <strong>transformational phase</strong>, pivoting from a volume-based exporter to a <strong>globally integrated, innovation-driven medical technology company</strong>. With strategic acquisitions, a strong domestic engine, deepening R&amp;D, and CAPEX-led capacity expansion, the <strong>long-term growth runway is robust‚Äîpotentially 20% CAGR or more in 3‚Äì5 years</strong>.</p>
<p>While <strong>FY26 growth is modest (~15‚Äì16%) due to macro headwinds</strong>, the <strong>second half is expected to accelerate</strong>, supported by base recovery, acquisition contributions, and product launches. <strong>H2 FY26 will be a key inflection point</strong>.</p>
<p><strong>Investor Takeaway</strong>: Short-term headwinds are priced in; medium-term upside is significant. Watch for: - Progress on <strong>synergies</strong> from Citieffe/PendraCare. - <strong>US policy/tariff resolution</strong>. - <strong>CE product launches and order wins in Europe</strong>. - Margin sustainability at &gt;26%.</p>
<blockquote>
<p>üìå <strong>POLYMED is a company building durable value‚Äîbest suited for long-term growth investors</strong>.</p>
</blockquote>
<hr />
<p><em>Note: All data and statements are based on unaudited disclosures, earnings calls, and press releases as of November 2025. Actual performance may vary based on audited results and evolving circumstances.</em></p>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
